HS-173 |
Catalog No.GC16713 |
HS-173 es un nuevo inhibidor de PI3K, que se utiliza para el tratamiento del cÁncer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1276110-06-5
Sample solution is provided at 25 µL, 10mM.
Phosphatidylinositol 3-kinase (PI3K) was first identified over 20 years ago as a lipid kinase associated with viral oncoproteins. PI3K signaling pathway regulates various cellular processes such as growth, cell cycle progression, apoptosis, migration, metabolism, and cytoskeleton rearrangement. HS-173 is a novel PI3K inhibitor.
In vitro: HS-173 inhibited the PI3K signaling pathway, and showed anti-proliferative effects on cancer cells. Also, HS-173 induced cell cycle arrest at the G2/M phase and apoptosis. In addition, HS-173 decreased the expression HIF-1a and VEGF which play an important role in angiogenesis. This effect was confirmed by the suppression of tube formation and migration assay in vitro [1].
In vivo: HS-173 diminished blood vessel formation in the Matrigel plug assay in mice. These results suggest that HS-173 has potent anti-angiogenic activity in vivo [1].
Clinical trials: Currenlty no clinical data are available.
Reference:
[1] Lee H, Jung KH, Jeong Y, Hong S, Hong SS. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett. 2013 Jan 1;328(1):152-9.
Average Rating: 5
(Based on Reviews and 19 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *